Format

Send to

Choose Destination
Nat Biotechnol. 2015 Apr;33(4):390-394. doi: 10.1038/nbt.3155. Epub 2015 Feb 18.

Inducible in vivo genome editing with CRISPR-Cas9.

Author information

1
Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY.
2
Hematology / Medical Oncology Division, Department of Medicine, Weill-Cornell Medical College, New York, NY.
3
Weill-Cornell / Rockefeller / Sloan Kettering Tri-Institutional MD-PhD program, New York, NY.
4
Gerstner Sloan Kettering Graduate School of Biomedical Sciences, New York, NY.
5
Bioinformatics Core facility, Memorial Sloan Kettering Cancer Center, New York, NY.
6
Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY.
#
Contributed equally

Abstract

CRISPR-Cas9-based genome editing enables the rapid genetic manipulation of any genomic locus without the need for gene targeting by homologous recombination. Here we describe a conditional transgenic approach that allows temporal control of CRISPR-Cas9 activity for inducible genome editing in adult mice. We show that doxycycline-regulated Cas9 induction enables widespread gene disruption in multiple tissues and that limiting the duration of Cas9 expression or using a Cas9(D10A) (Cas9n) variant can regulate the frequency and size of target gene modifications, respectively. Further, we show that this inducible CRISPR (iCRISPR) system can be used effectively to create biallelic mutation in multiple target loci and, thus, provides a flexible and fast platform to study loss-of-function phenotypes in vivo.

PMID:
25690852
PMCID:
PMC4390466
DOI:
10.1038/nbt.3155
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center